Skip to main content
SpringerLink
Log in
Book cover

Diagnostic and Therapeutic Advances in Pediatric Oncology pp 215–251Cite as

Osteosarcoma

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 92))

Abstract

Only three decades ago, osteosarcoma was considered incurable; treatment options were greeted with great skepticism and pessimism [1]. The recognition of the efficacy of adjuvant chemotherapy has allowed 70% of patients with osteosarcoma to be cured of their disease. With the advances in our understanding of the biology of osteosarcoma, we are poised to improve this cure rate even further. This chapter highlights the latest information on the biology and treatment of osteosarcoma.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Link MP, Eilber F. 1993. Osteosarcoma. In Pizzo PA, Poplack DG (eds.), Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott, pp. 841–866.

    Google Scholar 

  2. Siegal G, Dahlin D, Sim F. 1975. Osteoblastic osteogenic sarcoma in a 35–month old girl: report of a case. Am J Pathol 63:336–890.

    Google Scholar 

  3. Levy M, Jaffe N. 1982. Osteosarcoma in early childhood. Pediatrics 70(2):302–303.

    PubMed  CAS  Google Scholar 

  4. Luiz C, Al Kharusi W, Sethu A, Buhl L, Al Lamki Z. 1992. Osteosarcoma in a 26-month old girl. Cancer 70(4):894–896.

    PubMed  CAS  Google Scholar 

  5. Miller R, Yound J, Novakovic B. 1995. Childhood cancer. Cancer 75(Suppl l):395–405.

    PubMed  CAS  Google Scholar 

  6. Gurney J, Severson R, Davis S, Robison L. 1995. Incidence of cancer in children in the United States. Cancer 75(8):2186–2195.

    PubMed  CAS  Google Scholar 

  7. Dorfman H, Czerniak B. 1995. Bone cancers. Cancer 75(Suppl 1):203–210.

    CAS  Google Scholar 

  8. Huvos A. 1991. Bone Tumors: Diagnosis, Treatment and Prognosis. Philadelphia: W.B. Saunders.

    Google Scholar 

  9. Unni K. 1996. Dahlin’s Bone Tumors — General Aspects and Data on 11,087 Cases. Philadelphia, New York: Lippincott-Raven.

    Google Scholar 

  10. Parkin D, Stiller C, Nectoux J. 1993. International variations in the incidence of childhood bone tumours. Int J Cancer 53:371–376.

    PubMed  CAS  Google Scholar 

  11. Johnson L. 1953. Bull NY Acad Med 29:164–171.

    CAS  Google Scholar 

  12. Price C. 1958. Primary bone-forming tumours and their relationship to skeletal growth. J Bone Joint Surg 40B(3):574–593.

    Google Scholar 

  13. Fraumeni J. 1967. Stature and malignant tumors of bone in childhood and adolescence. Cancer 20(6):967–973.

    PubMed  Google Scholar 

  14. Tjalma R. 1966. Canine bone sarcoma: estimation of relative risk as a function of body size. J Natl Cancer Inst 36(6): 1137–1150.

    PubMed  CAS  Google Scholar 

  15. Loutit J. 1970. Malignancy from radium. Br J Cancer 24(2): 195–207.

    PubMed  CAS  Google Scholar 

  16. Tucker M, D’angio G, Boice J, et al. 1987. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317(10):588–593.

    PubMed  CAS  Google Scholar 

  17. Newton W, Meadows A, Shimada H, Bunin G, Vawter G. 1991. Bone sarcomas as second malignant neoplasms following childhood cancer. Cancer 67(1): 193–201.

    PubMed  Google Scholar 

  18. Toxicology and carcinogenesis studies of sodium fluoride (CAS No. 7681-49-4) in F344/N Rats and B6C3F Mice (Drinking water studies). 1990. NIH publication 91-2848.

    Google Scholar 

  19. Gelberg K, Fitzgerald E, Hwand S, Dubrow R. 1995. Fluoride exposure and childhood osteosarcoma: a case-control study. Am J Public Health 85(12):1678–1683.

    PubMed  CAS  Google Scholar 

  20. Schwartzbaum J, George S, Pratt C, Davis B. 1991. An exploratory study of environmental and medical factors potentially related to childhood cancer. Med Pediatr Oncol 19:115–121.

    PubMed  CAS  Google Scholar 

  21. Moss M, Kanarek M, Anderson H, Hanrahan L, Remington P. 1995. Osteosarcoma, seasonality and environmental factors in Wisconsin, 1979–1989. Arch Environ Health 50(3):235–241.

    PubMed  CAS  Google Scholar 

  22. Finkel MP, Biskis BO, Jinkins PB. 1966. Virus induction of osteosarcomas in mice. Science 151(711):698–701.

    PubMed  CAS  Google Scholar 

  23. Czitrom A, Pritzker K, Langer F, Gross A, Luk S. 1976. Virus-induced osteosarcoma in rats. J Bone Joint Surg 58-A(3):303–308.

    Google Scholar 

  24. Friedlander G, Mitchell M. 1976. A virally induced osteosarcoma in rats. J Bone Joint Surg 58-A(3):295–302.

    Google Scholar 

  25. Finkel M, Biskis B, Farrell C. 1968. Osteosarcomas appearing in syrian hamsters after treatment with extracts of human osteosarcomas. Proc Natl Acad Sci USA 60:1223–1230.

    PubMed  CAS  Google Scholar 

  26. Morton D, Malmgren R. 1968. Human osteosarcomas: immunologic evidence suggesting an associated infectious agent. Science 162:1279–1281.

    PubMed  CAS  Google Scholar 

  27. Yu AHW, Jaffe N, Parkman R. 1977. Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. N Engl J Med 297:121–127.

    PubMed  CAS  Google Scholar 

  28. Sinovic J, Bridge J, Neff J. 1992. Ring chromosome in parosteal osteosarcoma — clinical and diagnostic significance. Cancer Genet Cytogenet 62:50–52.

    PubMed  CAS  Google Scholar 

  29. Mertens F, Mandahl N, Orndal C, et al. 1993. Cytogenetic findings in 33 osteosarcomas. Int J Cancer 55:44–50.

    PubMed  CAS  Google Scholar 

  30. Hoogerwerf W, Hawkins A, Perlman E, Griffin C. 1994. Chromosome analysis of nine osteosarcomas. Genes Chromosomes Cancer 9:88–92.

    PubMed  CAS  Google Scholar 

  31. Ozisik Y, Meloni A, Peier A, Altungoz O, Spanier S, Zalupski M, Leong S, Sandberg A, 1994. Cytogenetic findings in 19 malignant bone tumors. Cancer 74(8):2268–2275.

    PubMed  CAS  Google Scholar 

  32. Tarkkanen M, Karhu R, Kallioniemi A, et al. 1995. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 55:1334–1338.

    PubMed  CAS  Google Scholar 

  33. Fletcher J, Gebhardt M, Kozakewich H. 1994. Cytogenetic aberrations in osteosarcomas. Cancer Genet Cytogenet 77:81–88.

    PubMed  CAS  Google Scholar 

  34. Yamaguchi T, Togushida J, Yamamoro T, et al. 1992. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 52:2419–2423.

    PubMed  CAS  Google Scholar 

  35. Look A, Douglass E, Meyer W. 1988. Clinical importance of near diploid tumor stem lines in patients with osteosarcoma of an extremity. N Engl J Med 318(24):1567–1572.

    PubMed  CAS  Google Scholar 

  36. Bauer HCF. 1993. Current status of DNA cytometry in osteosarcoma. In Humphrey GB (ed.), Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Boston: Kluwer, pp. 159–169.

    Google Scholar 

  37. Knudson AG Jr. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820–823.

    PubMed  Google Scholar 

  38. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323(6089):643–646.

    PubMed  CAS  Google Scholar 

  39. Fung YK, Murphree AL, T’Ang A, Qian J, Hinrichs SH, Benedict WF. 1987. Structural evidence for the authenticity of the human retinoblastoma gene. Science 236(4809):1657–1661.

    PubMed  CAS  Google Scholar 

  40. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. 1987. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235(4794):1394–1399.

    PubMed  CAS  Google Scholar 

  41. Abramson DH, Ellsworth RM, Zimmerman LE. 1976. Nonocular cancer in retinoblastoma survivors. Trans Am Acad Ophthalmol Otolaryngol 81(3 Pt l):454–457.

    CAS  Google Scholar 

  42. Abramson DH, Ellsworth RM, Kitchin FD, Tung G. 1984. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology 91(11): 1351–1355.

    PubMed  CAS  Google Scholar 

  43. Draper GJ, Sanders BM, Kingston JE. 1986. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53(5):661–671.

    PubMed  CAS  Google Scholar 

  44. Smith LM, Donaldson SS, Egbert PR, Link MP, Bagshaw MA. 1989. Aggressive management of second primary tumors in survivors of hereditary retinoblastoma. Int J Radiat Oncol Biol Phys 17(3):499–505.

    PubMed  CAS  Google Scholar 

  45. Gilman P, Wang N, Fan S, Reede J, Khan A, Leventhal B. 1985. Familial osteosarcoma associated with 13; 14 chromosomal rearrangement. Cancer Genet Cytogenet 17:123–132.

    PubMed  CAS  Google Scholar 

  46. Weichselbaum R, Cassady J, Jaffe N, Filler R. 1977. Preliminary results of aggressive multimodality therapy for metastatic osteosarcoma. Cancer 40:78–83.

    PubMed  CAS  Google Scholar 

  47. Benedict W, Fung Y, Murphree A. 1988. The gene responsible for the development of retinoblastoma and osteosarcoma. Cancer 62:1691–1694.

    PubMed  CAS  Google Scholar 

  48. Reissmann P, Simon M, Lee W, Slamon D. 1989. Studies of the retinoblastoma gene in human sarcomas. Oncogene 4:839–843.

    PubMed  CAS  Google Scholar 

  49. Toguchida J, Ishizaki K, Sasaki M, Ikenaga M, Sugimoto M, Kotoura Y, Yamamuro T. 1988. Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Cancer Res 48:3939–3943.

    PubMed  CAS  Google Scholar 

  50. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki M, Kotoura Y, Tamamuro T. 1994. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54:3042–3048.

    PubMed  CAS  Google Scholar 

  51. Huang H, Yee J, Shew J, et al. 1988. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563–1566.

    PubMed  CAS  Google Scholar 

  52. Toguchida J, Ishizaki K, Nakamura Y, Sasaki M, Ikenaga M, Kato M, Sugimoto M, Kotoura Y, Yamamuro T. 1989. Assignment of common allele loss in osteosarcoma to the subregion 17pl3. Cancer Res 49:6247–6251.

    PubMed  CAS  Google Scholar 

  53. Chang F, Syrjanen S, Syrjanen K. 1995. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13(4): 1009–1022.

    PubMed  CAS  Google Scholar 

  54. Lane DP. 1993. A death in the life of p53. Nature 362:786–787.

    PubMed  CAS  Google Scholar 

  55. Marx J. 1993. How p53 suppresses cell growth. Science 262:1644–1645.

    PubMed  CAS  Google Scholar 

  56. Yonish-Rouach E, Grunwald D, Wilder S, et al. 1993. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 13:1415–1423.

    PubMed  Google Scholar 

  57. Lavigueur A, Maltby V, Mock D, Rossant J. Pawson T, Bernstein A. 1989. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9(9):3982–3991.

    PubMed  CAS  Google Scholar 

  58. Masuda H, Miller C, Koeffler H, Battifora H, Cline M. 1987. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716–7719.

    PubMed  CAS  Google Scholar 

  59. Romano JW, Ehrhart JC, Duthu A, Kim CM, Appella E, May P. 1989. Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line. Oncogene 4(12):1483–1488.

    PubMed  CAS  Google Scholar 

  60. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP. 1990. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50(24):7950–7954.

    PubMed  CAS  Google Scholar 

  61. Chandar N, Billig B, McMaster J, Novak J. 1992. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 65(2):208–214.

    PubMed  CAS  Google Scholar 

  62. Toguchida J, Yamaguchi T, Ritchie B, et al. 1992. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194–6199.

    PubMed  CAS  Google Scholar 

  63. Ivarone A, Matthay K, Steinkirchner T, Israel M. 1992. Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci USA 89:4207–4209.

    Google Scholar 

  64. Malkin D, Li F, Strong L, et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238.

    PubMed  CAS  Google Scholar 

  65. Toguchida J, Yamaguchi T, Dayton S, et al. 1992. Prevalence and spectrum of germline mutations of the P53 gene among patients with sarcoma. N Engl J Med 326(20):1301–1308.

    PubMed  CAS  Google Scholar 

  66. Mcintyre J, Smith-Sorensen B, Friend S, et al. 1994. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 12(5):925–930.

    PubMed  CAS  Google Scholar 

  67. Porter D, Holden S, Steel C, Cohen B. Wallace M, Reid R. 1992. A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families. J Bone Joint Surg Br 74-B(6):883–886.

    Google Scholar 

  68. Oliner J, Kinzler K, Meltzer P, George K, Vogelstein B. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83.

    PubMed  CAS  Google Scholar 

  69. Ladanyi M, Cha C, Lewis R, Jhanwar S, Huvos A, Healey J. 1993. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 52:16–18.

    Google Scholar 

  70. Florenes V, Maelandsmo G, Forus A, Andreassen A, Myklebost O, Fodstad O. 1994. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Insl 86(17):1297–1302.

    CAS  Google Scholar 

  71. Miller C, Aslo A, Campbell M, Kawamata N, Lampkin B, Koeffler H. 1996. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 86:136–142.

    PubMed  CAS  Google Scholar 

  72. DePinho RA, Schreiber-Agus N, Alt FW. 1991. Myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 57:1–46.

    PubMed  CAS  Google Scholar 

  73. Henriksson M, Luscher B. 1996, The myc family of oncogenes. Adv Cancer Res 68:109–182.

    PubMed  CAS  Google Scholar 

  74. Isfort R, Cody D, Lovell G, Docrsen C. 1995. Analysis of oncogenes, tumor suppressor genes, autocrine growth-factor production, and differentiation state of human osteosarcoma cell lines. Mol Carcinogenesis 14:170–178.

    CAS  Google Scholar 

  75. Sturm S, Strauss P, Adolph S, Hameister H, Erfle V. 1990. Amplification and rearrangement of c-myc in radiation-induced murine osteosarcomas. Cancer Res 50:4146–4153.

    PubMed  CAS  Google Scholar 

  76. Masuda H, Battifora H, Yokota J, Meltzer S, Cline MJ. 1987. Specificity of proto-oncogene amplification in human malignant diseases. Mol Biol Med 4(4):213–227.

    PubMed  CAS  Google Scholar 

  77. Ikeda S, Sumii H, Akiyama K, Watanabe S, Ito S, Inoue H, Takechi H, Tanabe G, Oda T. 1989. Amplification of both c-myc and c-raf-1 oncogenes in human osteosarcoma. Jpn J Cancer Res 80:6–9.

    PubMed  CAS  Google Scholar 

  78. Ladanyi M, Park C, Lewis R, Jhanwar S, Healey J, Huvos A. 1993. Sporadic amplification of the myc gene in human osteosarcomas. Diagn Mol Pathol 2(3):163–167.

    PubMed  CAS  Google Scholar 

  79. Angel P, Karin M. 1991. The role of jun, fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072(2–3): 129–157.

    PubMed  CAS  Google Scholar 

  80. Radler-Pohl A, Gebel S, Sachsenmaier C, et al. 1993. The activation and activity control of AP-1 (fos/jun). Ann N Y Acad Sci 684:127–148.

    PubMed  CAS  Google Scholar 

  81. Ward JM, Young DM. 1976. Histogenesis and morphology of periosteal sarcomas induced by FBJ virus in N1H Swiss mice. Cancer Res 36(11 Pt l):3985–3992.

    PubMed  CAS  Google Scholar 

  82. Curran T, Peters G, Van Beveren C, Teich NM, Verma IM. 1982. FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J Virol 44(2):674–682.

    PubMed  CAS  Google Scholar 

  83. Ruther U, Garber C, Komitowski D, Muller R, Wagner EF. 1987. Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 325(6103):412–416.

    PubMed  CAS  Google Scholar 

  84. Ruther U, Komitowski D, Schubert FR, Wagner EF. 1989. c-fos expression induces bone tumors in transgenic mice. Oncogene 4(7):861–865.

    PubMed  Google Scholar 

  85. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF. 1992. Bone and haematopoietic defects in mice lacking c-fos. Nature 360(6406):741–745.

    PubMed  CAS  Google Scholar 

  86. Wang Z, Liang J, Schellander K, Wagner E, Grigoriadis A. 1995. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res 55:6244–6251.

    PubMed  Google Scholar 

  87. Schon A, Michiels L, Janowski M, Merregaert J, Erfle V. 1986. Expression of protooncogenes in murine osteosarcomas. Int J Cancer 38:67–74.

    PubMed  CAS  Google Scholar 

  88. Wang H, Rodgers W, Chrnell M, Svitek C, Schwartz H. 1995. Osteosarcoma oncogene expression detected by in situ hybridization. J Orthoped Res 13:671–678.

    CAS  Google Scholar 

  89. Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JW, Mercola D. 1990. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5(7):989–1000.

    PubMed  CAS  Google Scholar 

  90. Raymond A, Simms W, Ayala A. 1995. Osteosarcoma-specimen management following primary chemotherapy. Hematol Oncol Clin North Am 9(4):841–867.

    PubMed  CAS  Google Scholar 

  91. Schajowicz F, Sissons H, Sobin L. 1995. The World Health Organization’s histologic classification of bone tumors. Cancer 75(5):1208–1214.

    PubMed  CAS  Google Scholar 

  92. Ueda Y, Nakanishi I. 1989. Immunohistochemical and biochemical studies on the collagenous proteins of human osteosarcoma. Virchows Arch (B) 58:79–88.

    CAS  Google Scholar 

  93. Grundmann E, Ueda Y, Schneider-Stock R, Roessner A. 1995. New aspects of cell biology in osteosarcoma. Pathol Res Pract 191:563–570.

    PubMed  CAS  Google Scholar 

  94. Jundt G, Schultz A, Berghauser KH, Fisher LW, Gehron-Robey P, Termine JD. 1989. Immunocytochemical identification of osteogenic bone tumors by osteonectin antibodies. Virchows Arch (A) 414:345–353.

    CAS  Google Scholar 

  95. Bosse A, Vollmer E, Bocker W, Roessner A, Wuisman P, Jones D, Fisher LW. 1990. The impact of osteonectin for differential diagnosis of bone tumors. An immunohistochemical approach. Pathol Res Pract 186(5):651–657.

    PubMed  CAS  Google Scholar 

  96. Meyers P, Heller G, Heatey J, Huvos A, Applewhite A, Sun M, LaQuaglia M. 1993. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 11(3):449–453.

    PubMed  CAS  Google Scholar 

  97. Parham D, Pratt C, Parvey L, Webber B, Champion J. 1985. Childhood multifocal osteosarcoma: clinicopathologic and radiologic correlates. Cancer 55(11):5653–2658.

    Google Scholar 

  98. Kesselring FO, Penn W. 1982. Radiological aspects of “classic” primary osteosarcoma: value of some radiological investigations: a review. Diagn Imaging 51(2):78–92.

    PubMed  CAS  Google Scholar 

  99. Gillespy T, Manfrini M, Ruggieri P, Spanier SS, Pettersson H, Springfield DS. 1988. Staging of intraosseous extent of osteosarcoma: correlation of preoperative CT and MR imaging with pathologic macroslides. Radiology 167(3):765–767.

    PubMed  Google Scholar 

  100. Murphy WA. 1991. Imaging bone tumors in the 1990’s. Cancer 67(4):1169–1176.

    PubMed  Google Scholar 

  101. Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA. 1992. Pediatric musculoskeletal tumors: use of dynamic contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology 184:243–248.

    PubMed  CAS  Google Scholar 

  102. Van der Woude HJ, Bloom JL, Schipper J, et al. 1994. Changes in tumor perfusion induced by chemotherapy in bone sarcomas: color doppler flow imaging compared with contrast-enhanced MR imaging and 3–phase bone scintigraphy. Radiology 191:421–431.

    PubMed  Google Scholar 

  103. Mooyaarl EL, Kamman RL, Boeve WJ. 1993. In vivo 31P nuclear magnetic resonance spectroscopy of osteosarcoma. In Humphrey GB (ed.), Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Boston: Kluwer, pp. 19–24.

    Google Scholar 

  104. Rosen G, Loren G, Ramanna L. 1991. Osteogenic sarcoma: early evaluation of preoperative chemotherapy with thallium-201 scintigraphy. Proc Am Soc Clin Oncol: 97.

    Google Scholar 

  105. Rosen G. 1993. An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma. In Humphrey GB (eds.). Osteosarcoma in Adolescents and Young Adults: New Developments and Controversie. Boston: Kluwer, pp. 49–54.

    Google Scholar 

  106. Tse N, Hoh C, Hawkins R, Phelps M, Glaspy J. 1994. Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma. Am J Clin Oncol 17:22–25.

    PubMed  CAS  Google Scholar 

  107. Hoefnagel CA, Bruning PF, Cohen P, Marcuse HR, van der Schoot JB. 1981. Detection of lung metastases from osteosarcoma by scintigraphy using 99mTc-methylene diphosphonate. Diagn Imaging 50(5):277–284.

    PubMed  CAS  Google Scholar 

  108. Aboulafia A, Malawer M. 1993. Surgical management of pelvic and extremity osteosarcoma. Cancer 71:3358–3366.

    PubMed  CAS  Google Scholar 

  109. Murray J, Jessup K, Romsdahi M, et al. 1985. Limb-salvage surgery in osteosarcoma: early experience at MD Anderson Hospital and Tumor Institute. Cancer Treatment Symp 3:131–137.

    CAS  Google Scholar 

  110. Meyers P, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G. 1992. Chemotherapy for nonmetaslatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10(1):5–15.

    PubMed  CAS  Google Scholar 

  111. Rosenberg ZS, Lev S, Schmahmann S, Steiner GC, Beltran J, Present D. 1995. Osteosarcoma: subtle, rate, and misleading plain film features. Am J Radiol 165:1209–1214.

    CAS  Google Scholar 

  112. Davis A, Bell R, Goodwin P. 1994. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12(2):423–431.

    PubMed  CAS  Google Scholar 

  113. Bacci G, Picei P, Ferrari S, Oralndi M, Ruggieri P, Casadei R, Ferraro A, Biagini R, Battistini A. 1993. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 71(4):1224–1230.

    PubMed  CAS  Google Scholar 

  114. Bentzen S, Poulsen H, Kaai S, Jensen O, Johansen H, Mouridsen H, Daugaard S, Arnoldi C. 1988. Prognostic factors in osteosarcoma. Cancer 62(1):194–202.

    PubMed  CAS  Google Scholar 

  115. Taylor W, Ivins J, Unni K, Beabout J, Gelenzer H, Black L. 1989. Prognostic variables in osteosarcoma: a multi-institutional study. J Natl Cancer Inst 81(l):21–30.

    PubMed  CAS  Google Scholar 

  116. Rosen G, Murphy M, Huvos A, Gutierrez M, Marcove R. 1976. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37(1):1–11.

    PubMed  CAS  Google Scholar 

  117. Raymond A, Chawla S, Carrasco C. 1987. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 4:212–236.

    PubMed  CAS  Google Scholar 

  118. Winkler K, Beron G, Delling G. 1988. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337.

    PubMed  CAS  Google Scholar 

  119. Glasser D, Lane J, Huvos A, Marcove R, Rosen G. 1992. Survival, prognosis, and therapeutic response in osteogenic sarcoma. Cancer 69(3):698–708.

    PubMed  CAS  Google Scholar 

  120. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. 1995. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome [see comments]. N Engl J Med 333(21):1380–1385.

    PubMed  CAS  Google Scholar 

  121. Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gotlesman MM, Pastan I.1986. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83(12):4538–4542.

    PubMed  CAS  Google Scholar 

  122. Callen DF, Baker E, Simmers RN, Soshadri R, Roninson IB. 1987. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 77(2): 142–144.

    PubMed  CAS  Google Scholar 

  123. Endicott JA, Ling V. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137–171.

    PubMed  CAS  Google Scholar 

  124. Goldstein LJ, Galski H, Fojo A, et al. 1989. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81 (2):116–124.

    PubMed  CAS  Google Scholar 

  125. Schwartz C, Rosier R, Willis J, Hicks D. 1992. P-glycoprotcin (P-gp) expression in osteosarcoma and clinical outcome (meeting abstract). Proc Am Soc Clin Oncol 11:A948.

    Google Scholar 

  126. Chan H, DeBoer G, Haddad G, Gallie B, Ling V. 1995. Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am 9(2):275–318.

    PubMed  CAS  Google Scholar 

  127. Wunder JS, Bell RS, Wold L, Andrulis IL. 1993. Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Orthoped Res 11(3):396–403.

    CAS  Google Scholar 

  128. Serra M, Scotlandi K, Manara MC, Maurici D, Benini S, Sarti M, Campanacci M, Baldini N. 1995. Analysis of P-glycoprotein expression in osteosarcoma. Eur J Cancer 31A(12):1998–2002.

    PubMed  CAS  Google Scholar 

  129. Stein U, Wunderlich V, Haensch W, Schmidt-Peter P. 1993. Expression of the mdrl gene in bone and soft tissue sarcomas of adult patients. Eur J Cancer 29A(14):1979–1981.

    PubMed  CAS  Google Scholar 

  130. Li W, Fan J, Hochhauser D, et al. 1995. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 91:10436–10440.

    Google Scholar 

  131. Winkler K, Bieling P, Bielack S. 1992. Die chemotherapie des osteosarkoms. Z Othosp 138:285–289.

    Google Scholar 

  132. Fuchs N, Winkler K. 1993. Osteosarcoma. Curr Opinion Oncol 5:667–671.

    CAS  Google Scholar 

  133. Picei P, Sangiorgi L, Rougraff B, Neff J, Casadei R, Campanacci M. 1994. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 12(12):2699–2705.

    Google Scholar 

  134. Jaffe N, Frei E, Taggis D, Bishop Y. 1974. Adjuvant methotrexate and citrovorum factor treatment of osteogenic sarcoma. N Engl J Med 291:994–997.

    PubMed  CAS  Google Scholar 

  135. Cortes EP, Holland JF, Wang JJ, Sinks LF, Blom J, Senn H, Bank A, Glidewell O. 1974. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 291:998–1000.

    PubMed  CAS  Google Scholar 

  136. Baum E, Greenberg L, Gaynon P, Krivit W, Hammond D. 1978. Use of cis-platinum diammine dichloride (CPDD) in osteogenic sarcoma (OS) in children. Proc Am Assoc Cancer Res 19:385.

    Google Scholar 

  137. Grem JL, King SA, Wittes RE, Leyland-Jones B. 1988. The role of methotrexate in osteosarcoma. J Natl Cancer Inst 80:626–656.

    PubMed  CAS  Google Scholar 

  138. Taylor WF, Ivins JC, Dahlin DC, Edmonson JH, Pritchard DJ. 1978. Trends and variability in survival from osteosarcoma. Mayo Clin Proc 53(11):695–700.

    PubMed  CAS  Google Scholar 

  139. Edmonson JH, Green SJ, Ivins JC, Gilchrist GS, Cregan ET, Pritchard DJ, Smithson WA, Dahlin DC, Taylor WF. 1980. Methotrexate as adjuvant treatment for primary osteosarcoma (letter). N Engl J Med 303(11):642–643.

    PubMed  CAS  Google Scholar 

  140. Taylor WF, Ivins JC, Pritchard DJ, Dahlin DC, Gilchrist GS, Edmonson JH. 1985. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc 60(2):91–104.

    PubMed  CAS  Google Scholar 

  141. Jaffe N, Patel S, Benjamin R. 1995. Chemotherapy in osteosarcoma: basis for application and antagonism to implementation; early controversies surrounding its implementation. Hematol Oncol Clin North Am 9(4):825–839.

    PubMed  CAS  Google Scholar 

  142. Link M, Goorin A, Miser A, et al. 1986. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314(25):1600–1606.

    PubMed  CAS  Google Scholar 

  143. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. 1987. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5(l):21–26.

    PubMed  CAS  Google Scholar 

  144. Marti C, Kroner T, Remagen W, Berchtold W, Cserhati M, Varini M. 1985. High dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 69(1):115–117.

    PubMed  CAS  Google Scholar 

  145. Cassano WF, Graham-Pole J, Dickson N. 1991. Etoposide, cyclophosphamide, cisplatin, and doxorubicin as neoadjuvant chemotherapy for osteosarcoma. Cancer 68(9):1899–1902.

    PubMed  CAS  Google Scholar 

  146. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. 1994. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 12(7):1443–1451.

    PubMed  CAS  Google Scholar 

  147. Rosier RN, Teot LA, Hicks DG, Schwartz C, O’keefe RJ, Puzas JE. 1995. Multiple drug resistance in osteosarcoma. Iowa Orthopaed J 15:66–73.

    CAS  Google Scholar 

  148. Winkler K, Beron G, Kotz R, et al, 1984. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a coorperative German/Austrian study. J Clin Oncol 2(6):617–624.

    PubMed  CAS  Google Scholar 

  149. Kleinerman E, Erickson K, Schroit A, et al. 1983. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 43:2010–2014.

    PubMed  CAS  Google Scholar 

  150. Fidler I, Sone S, Fogler W, et al. 1981. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 58:1680–1684.

    Google Scholar 

  151. Fidler I, Barnes Z, Fogler W, et al. 1982. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res 42:496–501.

    PubMed  CAS  Google Scholar 

  152. MacEwen E, Kurzman I, Rosenthal R, et al. 1989. Therapy of osteosarcoma in dogs with intravenous injection of liposome encapsulated muramyl tripeptide. J Natl Cancer Inst 81:935–937.

    PubMed  CAS  Google Scholar 

  153. Murray J, Kleinerman E, Cunningham J, et al. 1989. Phase I trial of liposomal muramyl tripeptidephosphatidylethanolamine in cancer patients. J Clin Oncol 7:1915–1925.

    PubMed  CAS  Google Scholar 

  154. Kleinerman E, Gano J, Johnston D, Benjamin R, Jaffe N. 1995. Efficacy of liposomal muramyl tripepetide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 18(2):93–99.

    PubMed  CAS  Google Scholar 

  155. Kleinerman E, Snyder J, Jaffe N. 1991. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phophatidylethanolamine in children with osteosarcoma. J Clin Oncol 9(2):259–267.

    PubMed  CAS  Google Scholar 

  156. Pollak M, Sem AW, Richard M, Tetenes E, Bell R. 1992. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 84:966–971.

    PubMed  CAS  Google Scholar 

  157. Chavez-Kappel C, Velez-Yanguas M, Hirschfeld S, Helman L. 1994. Human osteosarcoma cell lines are dependent on Insulin-like growth factor I for in vitro growth. Cancer Res 54:2803–2807.

    Google Scholar 

  158. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M, Armatis P. 1995. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst 87(23):1787–1794.

    PubMed  CAS  Google Scholar 

  159. Folkman J. 1995. Clinical applications of research on angiogenesis. N Engl J Med 333(26):1157–1163.

    Google Scholar 

  160. Mori S, Ueda T, Kuratsu S, Hosono N, Izawa K, Uchida A. 1995. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 61(1):148–152.

    PubMed  CAS  Google Scholar 

  161. Morishita T, Mii Y, Miyauchi Y, et al. 1995. Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats. Jpn J Clin Oncol 25(2):25–31.

    PubMed  CAS  Google Scholar 

  162. Martinez A, Goffinet D, Donaldson S, Bagshaw M, Kaplan H. 1985. Intra-arterial infusion of radiosensitizer (BUdR) combined with hypofractionated irradiation and chemotherapy for primary treatment of osteogenic sarcoma. J Radiat Oncol Biol Phys 11(1):123–128.

    CAS  Google Scholar 

  163. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51(23 Pt 1):6304–6311.

    PubMed  CAS  Google Scholar 

  164. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89(16):7491–7495.

    PubMed  CAS  Google Scholar 

  165. Rab G, Wins J, Childs D, Cupps R, Pritchard D. 1976. Elective whole lung irradiation in the treatment of osteogenic sarcoma. Cancer 38:939–942.

    PubMed  CAS  Google Scholar 

  166. Jaffe N, Paed D, Farber S, et al. 1973. Favorable response of metastatic osteogenic sarcoma to pulse high dose methotrexate with citrovorum rescue and radiation therapy. Cancer 31(6):1367–1373.

    PubMed  CAS  Google Scholar 

  167. Rosen G, Tefft M, Martinez A, Cham W, Murphy M. 1975. Combination chemotherapy and radiation therapy in the treatment of metastatic osteogenic sarcoma. Cancer 35(3):622–630.

    PubMed  CAS  Google Scholar 

  168. Miser J, Arndt C, Smithson W, et al. 1994. Treatment of high grade osteosarcoma with ifosfamide, mesna, adriamycin, high dose methotrexate with or without cisplatin. Results of two pilot trials. Proc ASCO 13:421.

    Google Scholar 

  169. Goorin A, Shuster J, Baker A, Horowitz M, Meyer W, Link M. 1991. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the Multiinstitutional Osteosarcoma Study. J Clin Oncol 9(4):600–605,

    PubMed  Google Scholar 

  170. Giuliano A, Feig S, Eilber F. 1984. Changing metastatic patterns of osteosarcoma. Cancer 54:2160–2164.

    PubMed  CAS  Google Scholar 

  171. Tabone M, Kalifa C, Rodary C, Raquin M, Couanet D, Lemerle J. 1994. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 12(12):2614–2620.

    PubMed  CAS  Google Scholar 

  172. Jaffe N, Smith E, Abelson H, Frei E. 1983. Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin Oncol l(4):251–254.

    Google Scholar 

  173. Rosenberg S, Flye M, Conkle D, Geipp C, Levine A, Simon R. 1979. Treatment of osteogenic sarcoma: aggressive resection of pulmonary metastases. Cancer Treatment Rep 63(5):753–756.

    Google Scholar 

  174. Putnam J, Roth J, Wesley M, Johnston M, Rosenberg S. 1983. Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann Thorac Surg 36(5):516–523.

    PubMed  Google Scholar 

  175. Goorin A, Delorey M, Lack E, et al. 1984. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 2(5):425–431.

    PubMed  CAS  Google Scholar 

  176. Meyer W, Schell M, Kumar A, et al. 1987. Thoracotomy for pulmonary metastatic osteosarcoma: an analysis of prognostic indicators of survival. Cancer 59:374–379.

    PubMed  CAS  Google Scholar 

  177. Belli L, Scholl S, Livartowski A, et al. 1989. Resection of pulmonary metastases in osteosarcoma: a retrospective analysis of 44 patients. Cancer 63:2546–2550.

    PubMed  CAS  Google Scholar 

  178. Pastorino U, Gasparini M, Tavecchio L, et al. 1991. The contribution of salvage surgery to the management of childhood osteosarcoma. J Clin Oncol 9(8):1357–1362.

    PubMed  CAS  Google Scholar 

  179. Pastorino U, Gasparini M, Azzarelli A, Tavecchio L, Racasi G. 1993. Salvage surgery for childhood osteosarcoma. In Humphrey G (ed.), Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Boston: Kluwer Academic.

    Google Scholar 

  180. Ward W, Mikaelian K, Dorey F, Mirra J, Sassoon A, Holmes E, Eilber F, Eckardt J. 1994. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 12(9):1849–1858.

    PubMed  CAS  Google Scholar 

  181. Steinherz LJ, Steinherz PG, Tan C. 1995. Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 24(6):352–361.

    PubMed  CAS  Google Scholar 

  182. Steinherz LJ, Graham T. Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, Sandor G, Benson L, Williams R. 1992. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 89(5 Pt l):942–949.

    PubMed  CAS  Google Scholar 

  183. Schwartz CL, Hobbie WL, Truesdell S, Constine LC, Clark EB. 1993. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 11(10):1906–1910.

    PubMed  CAS  Google Scholar 

  184. Schwartz CL, Hobbie WL, Ruble K, Hinkle A, Constine LS. 1996. Long term nephrotoxicity and ototoxicity after cisplatin (CDDP) therapy. Proc 4th Int Conf on Long Term Complications of Treatment of Children and Adolescents for Cancer, Buffalo, NY.

    Google Scholar 

  185. Nicholson HS, Byrne J. 1993. Fertility and pregnancy after treatment for cancer during childhood or adolescence. Cancer 71(Suppl 10):3392–3399.

    PubMed  CAS  Google Scholar 

  186. Bieling P, Rehan N, Winkler P, et al. 1996. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14(3):848–858.

    PubMed  CAS  Google Scholar 

  187. Link M. 1993. Results of the MIOS. In Humprey G (ed.), Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Boston: Kluwer.

    Google Scholar 

  188. Rosen G, Caparros B, Huvos AG, et al. 1982. Preoperative therapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49(6):1221–1230.

    PubMed  CAS  Google Scholar 

  189. Winkler K, Bielack S, Delling G, Jurgens H, Kotz R, Salzer-Kuntschik M. 1993. Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). In Humphrey G (ed.), Cancer Treatment and Research: Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Boston: Kluwer.

    Google Scholar 

  190. Winkler K, Bielack S, Delling G, et al. 1990. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer 66(8):1703–1710.

    PubMed  CAS  Google Scholar 

  191. Provisor A, Nachman J, Krailo M, Ettinger L, Hammond D. 1987. Treatment of non-metastatic osteogenic sarcoma of the extremities with pre-and post-operative chemotherapy. Proc ASCO 6:217.

    Google Scholar 

  192. Miser JS, Krailo M. 1993. The Children’s Cancer Group Studies. In Humphrey G (ed.). Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Boston: Kluwer.

    Google Scholar 

  193. Bramwell VHC, Burger M, Sneath R, et al. 1992. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 10(10):1579–1591.

    PubMed  CAS  Google Scholar 

  194. Mirra JM. 1989. Bone Tumors: Clinical, Radiologic, and Pathologic Correlations. Philadelphia: Lea & Febiger.

    Google Scholar 

Download references

Authors
  1. Jeffrey S. Dome
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cindy L. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois, USA

    David O. Walterhouse M.D.  & Susan L. Cohn M.D.  & 

  2. Department of Pediatrics, Children’s Memorial Hospital, Chicago, Illinois, USA

    David O. Walterhouse M.D.  & Susan L. Cohn M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dome, J.S., Schwartz, C.L. (1997). Osteosarcoma. In: Walterhouse, D.O., Cohn, S.L. (eds) Diagnostic and Therapeutic Advances in Pediatric Oncology. Cancer Treatment and Research, vol 92. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5767-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5767-8_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7643-9

  • Online ISBN: 978-1-4615-5767-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation